OncoSec Medical Inc (ONCSQ)

[hschlauch]

Jon, this is exactly the one to watch in my opinion. I want to see what the multigene construct(s) will contain. There is one particular antibody that I hope is encoded on the plasmid - anti-CTLA-4. That antibody delivered intratumorally will allow CD28 on t cells to bind with their ligands on antigen presenting cells, e.g.dendritic cells. That will drive a tumor antigen specific immune response. CTLA-4 outcompetes CD28 for the same ligands on APC; therefore by blocking that checkpoint in the presence of APC, you allow CD28 to do its job of stimulating an immune response.

This would probably be required in advance of a systemic PD-1 checkpoint inhibitor.

I haven't yet discovered any company encoding multiple genes on plasmids that are delivered INTRATUMORALLY. This by itself is a big deal because there is mounting evidence that in situ vaccinations, i.e. local delivery, can lead to abscopal effects. Adding in an encoded checkpoint inhibitor like an anti-CTLA-4 antibody to an intratumorally delivered plasmid vehicle would potentially be worth billions of dollars.